Loading…
Ampersand Capital Partners
Actively investingGMP manufacturingInvest in manufacturing-intensive life-sciences businesses — CDMOs, fill-finish, single-use, and QC/analytics infrastructure — where operational scale-up creates durable value.
About
Growth-equity firm specializing in the life-sciences tools, CDMO, and pharma-services sectors — backing companies that build and scale GMP manufacturing capacity.
Investment thesis
Invest in manufacturing-intensive life-sciences businesses — CDMOs, fill-finish, single-use, and QC/analytics infrastructure — where operational scale-up creates durable value.
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Manufacturing focus iAdds 25 points if the firm flags GMP-manufacturing interest, plus 9 points per manufacturing-related technical interest listed (sterile injectables, fill-finish, GMP software, QC automation, and similar), capped at 45, and 10 points per manufacturing strategic category (CDMO investments, manufacturing infrastructure, continuous manufacturing, and similar), capped at 30. Levels: 75+ Manufacturing-focused | 50-74 Manufacturing-active | 25-49 Selective | below 25 Therapeutics-focused. Whether this dimension matters for you depends on your specific project.
100Manufacturing-focused
Portfolio strength iAdds 4 points per portfolio company, capped at 50, plus 6 points per realized exit, acquisition, or IPO, capped at 30, and a further 7 points per IPO, capped at 20. Shows 0 with a Building label when no portfolio companies are listed. Levels: 80+ Proven track record | 60-79 Strong | 40-59 Active | below 40 Emerging. Whether this dimension matters for you depends on your specific project.
48Active
Syndicate network iAdds 5 points per co-investor listed, capped at 40, plus 9 points for each frequent or recurring co-investor relationship, capped at 35, and 9 points for each strategic partner (corporate, pharma, crossover, or sovereign investor), capped at 25. Shows 0 with an Emerging label when no co-investors are listed. Levels: 75+ Deeply networked | 50-74 Well-connected | 25-49 Building network | below 25 Emerging. Whether this dimension matters for you depends on your specific project.
63Well-connected
Mfg due-diligence iScores each diligence area by depth (3 points expert, 2 in-depth, 1 standard) times 2, capped at 45, plus 5 points per recognized regulatory framework covered (FDA, EMA, MHRA, PMDA, and similar), capped at 25, plus 20 points for in-house or hybrid technical diligence capability (12 for external), and 10 if the firm reviews inspection history. Levels: 80+ Expert diligence | 60-79 Rigorous | 35-59 Standard | below 35 Light. Whether this dimension matters for you depends on your specific project.
100Expert diligence
Preferred stages
GrowthLate-stage
Therapeutic focus
BiologicsCell & gene therapyDiagnostics
Geographic focus
North AmericaEuropean Union
ACP
Ampersand Capital Partners
VC / Investment firm · United States
Live record · illustrative seed data · scores deterministic, rules-based — not AI.